Cited by 296Glioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Yen, K E, Bittinger, M A, Su, S M, Fantin, V R·2010·Oncogene

DOI 10.1038/onc.2010.444

Open this paper in CoChat — free account

Abstract

The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology. The nature of the heterozygous, point mutations mapping to arginine residues involved in the substrate binding inspired several research teams to investigate their impact on the biochemical activity of these enzymes. Soon, it became clear that the mutations identified impaired the ability of IDH1 and IDH2 to catalyze the conversion of isocitrate to α-ketoglutarate (αKG), whereas conferring a gain of a novel enzymatic activity leading to the reduction of αKG to the metabolite D2-hydroxyglutarate (D-2HG). Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value. Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.444

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337

Show all 63 references

Sorted by citations

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways
Park, J., Chen, Y., Tishkoff, D. X., Peng, C., Tan, M., Dai, L., Xie, Z., Zhang, Y., Zwaans, B. M. M., Skinner, M. E., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.06.001 · Cited by 1,000
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T. T., Stegle, O., Kohlbacher, O., Sander, C., Johnson, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 906
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Self-citation
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 590
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559
The emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2017) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 586
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Küçük, C., de Leval, L., Jaïs, J., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 522
Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
Andronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Self-citation
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 411
Cancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385
Chemistry and biochemistry of 13 C hyperpolarized magnetic resonance using dynamic nuclear polarization
Keshari, K. R., & Wilson, D. M. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60124b · Cited by 357
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M. C., Zhu, L. D., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.28 · Cited by 349
Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma
Li, Z., Wang, Y., Yu, J., Guo, Y., & Cao, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-05848-2 · Cited by 346
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation
Kudo, Y., Tateishi, K., Yamamoto, K., Yamamoto, S., Asaoka, Y., Ijichi, H., Nagae, G., Yoshida, H., Aburatani, H., & Koike, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02213.x · Cited by 285
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S. H., Tanguturi, S. K., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 262
The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 267
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Fritcher, E. G. B., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 243
Mitochondria in cancer
Grasso, D., Zampieri, L. X., Capelôa, T., de Velde, J. A. V., & Sonveaux, P. (2020) · Cell Stress · doi:10.15698/cst2020.06.221 · Cited by 238
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
5-hydroxymethylcytosine and its potential roles in development and cancer
Pfeifer, G. P., Kadam, S., & Jin, S. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-10 · Cited by 205
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Popovici-Müller, J. V., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Größ, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 204
Self-citation
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Dinardo, C. D., PROPERT, K. J., Loren, A. W., Paietta, E. M., Sun, Z., Levine, R. L., Straley, K. S., Yen, K. E., Patel, J. P., Agresta, S. V., et al. (2013) · Blood · doi:10.1182/blood-2013-03-493197 · Cited by 210
Self-citation
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene
Hall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 191
Mitochondrial Subversion in Cancer
Chatterjee, A., Dasgupta, S., & Sidransky, D. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0326 · Cited by 185
Modeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 187
SIRT3 and cancer: Tumor promoter or suppressor?
Alhazzazi, T. Y., Kamarajan, P., Verdin, E. M., & Kapila, Y. L. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.04.004 · Cited by 181
Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas
Elkhaled, A., Jalbert, L. E., Phillips, J. J., Yoshihara, H. A. I., Parvataneni, R., Srinivasan, R., Bourne, G., Berger, M. S., Chang, S. M., Cha, S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002796 · Cited by 180
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics
Kirtonia, A., Gala, K., Fernandes, S. G., Pandya, G., Pandey, A. K., Sethi, G., Khattar, E., & Garg, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.006 · Cited by 176
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 178
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Kernytsky, A. M., Wang, F., Hansen, E., Schalm, S. S., Straley, K. S., Gliser, C., Yang, H. Q., Travins, J. M., Murray, S., Dorsch, M., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 181
Self-citation
Metabolism unhinged: IDH mutations in cancer
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Nature Medicine · doi:10.1038/nm0311-291 · Cited by 175
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms
Qi, S., Yu, L., LI, H., Ou, Y.-H., Qiu, X., Ding, Y., Han, H.-X., & ZHANG, X. (2014) · Oncology Letters · doi:10.3892/ol.2014.2013 · Cited by 172
Cancer research: past, present and future
Cao, Y., DePinho, R. A., Ernst, M., & Vousden, K. H. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3138 · Cited by 170
Anticancer Agents That Counteract Tumor Glycolysis
Granchi, C., & Minutolo, F. (2012) · ChemMedChem · doi:10.1002/cmdc.201200176 · Cited by 167
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
Targeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 164
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 169
Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function
Rajeshkumar, N. V., Dutta, P., Yabuuchi, S., de Wilde, R. F., Martinez, G. V., Le, A., Kamphorst, J. J., Rabinowitz, J. D., Jain, S. K., Hidalgo, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0108 · Cited by 158
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Huang, J., Yu, J., Tu, L., Huang, N., Li, H., & Luo, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00506 · Cited by 147
PHGDH amplification and altered glucose metabolism in human melanoma
Mullarky, E., Mattaini, K. R., Heiden, M. G. V., Cantley, L. C., & Locasale, J. W. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00919.x · Cited by 153
Systemic Immunometabolism: Challenges and Opportunities
Lercher, A., Baazim, H., & Bergthaler, A. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.012 · Cited by 143
Mitochondrial fission‐fusion as an emerging key regulator of cell proliferation and differentiation
Mitra, K. (2013) · BioEssays · doi:10.1002/bies.201300011 · Cited by 134
Molecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 134
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 125
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
Emir, U. E., Larkin, S. J., de Pennington, N., Voets, N., Plaha, P., Stacey, R. J., Al-Qahtani, K., McCullagh, J., Schofield, C. J., Clare, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0934 · Cited by 123
The role of 5-hydroxymethylcytosine in human cancer
Pfeifer, G. P., Xiong, W., Hahn, M. A., & Jin, S. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1896-7 · Cited by 118
Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 116
In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors
Salamanca-Cardona, L., Shah, H., Poot, A. J., Correa, F. M., Di Gialleonardo, V., Lui, H., Miloushev, V. Z., Granlund, K. L., Tee, S. S., Cross, J. R., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.001 · Cited by 106
FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2021) · Cancers · doi:10.3390/cancers14010087 · Cited by 111
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 107
Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
Kerr, D. A., Lopez, H. U., Deshpande, V., Hornicek, F. J., Duan, Z., Zhang, Y., Rosenberg, A. E., Borger, D. R., & Nielsen, G. P. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827ab703 · Cited by 105
TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
Todisco, S., Convertini, P., Iacobazzi, V., & Infantino, V. (2019) · Cancers · doi:10.3390/cancers12010068 · Cited by 105
MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
Tanaka, H., Sasayama, T., Tanaka, K., Nakamizo, S., Nishihara, M., Mizukawa, K., Kohta, M., Koyama, J., Miyake, S., Taniguchi, M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1027-9 · Cited by 96
Molecular characterization of gallbladder cancer using somatic mutation profiling
Javle, M. M., Rashid, A., Churi, C. R., Kar, S., Zuo, M., Eterovic, A. K., Nogueras‐González, G. M., Jankú, F., Shroff, R. T., Aloia, T. A., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.11.001 · Cited by 87
IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma
Esmaeili, M., Hamans, B. C., Navis, A. C., van Horssen, R., Bathen, T. F., Gribbestad, I. S., Leenders, W. P. J., & Heerschap, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0008 · Cited by 86
Non-glucose metabolism in cancer cells—is it all in the fat?
Biswas, S., Lunec, J., & Bartlett, K. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9384-6 · Cited by 86
Extracellular RNA mediates and marks cancer progression
Redzic, J. S., Balaj, L., van der Vos, K. E., & Breakefield, X. O. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.010 · Cited by 86
Melanoma epigenetics: novel mechanisms, markers, and medicines
Lee, J. J., Murphy, G. F., & Lian, C. G. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.87 · Cited by 85
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer
Jia, X.-Q., Zhang, S., Zhu, H., Wang, W., Zhu, J., Wang, X., & Qiang, J. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.03.006 · Cited by 85
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
Jalbert, L. E., Elkhaled, A., Phillips, J. J., Neill, E., Williams, A. A., Crane, J. C., Olson, M. P., Molinaro, A. M., Berger, M. S., Kurhanewicz, J. V., et al. (2017) · Scientific Reports · doi:10.1038/srep44792 · Cited by 80
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma
Nagashima, H., Tanaka, K., Sasayama, T., Irino, Y., Sato, N., Takeuchi, Y., Kyotani, K., Mukasa, A., Mizukawa, K., Sakata, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now090 · Cited by 76
IDH1 mutations induce organelle defects via dysregulated phospholipids
Lita, A., Pliss, A., Kuzmin, A. N., Yamasaki, T., Zhang, L., Dowdy, T., Burks, C., de Val, N., Celiku, O., Ruiz‐Rodado, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20752-6 · Cited by 72
Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges
Nicholas, M. K., Lukas, R. V., Chmura, S. J., Yamini, B., Lesniak, M. S., & Pytel, P. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.009 · Cited by 73
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Liquid biopsies to occult brain metastasis
Rehman, A. U., Κhan, P., Maurya, S. K., Siddiqui, J. A., Santamaria‐Barria, J. A., Batra, S. K., & Nasser, M. W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01577-x · Cited by 72
Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes
Jin, Y., Elalaf, H., Watanabe, M., Tamaki, S., Hineno, S., Matsunaga, K., Woltjen, K., Kobayashi, Y., Nagata, S., Ikeya, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131998 · Cited by 70
IDH Mutations in Human Glioma
Kim, W. B., & Liau, L. M. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.009 · Cited by 71
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity
Xie, X., Baird, D., Bowen, K. E., Čápka, V., Chen, J., Chenail, G., Cho, Y., Dooley, J., Farsidjani, A., Fortin, P. D., et al. (2017) · Structure · doi:10.1016/j.str.2016.12.017 · Cited by 70
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
IDH mutation status in prostate cancer
Ghiam, A. F., Cairns, R. A., Thoms, J., Pra, A. D., Ahmed, O., Meng, A. X., Mak, T. W., & Bristow, R. G. (2011) · Oncogene · doi:10.1038/onc.2011.546 · Cited by 71
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation
Granchi, C., Roy, S., Simone, A. D., Salvetti, I., Tuccinardi, T., Martinelli, A., Macchia, M., Lanza, M., Betti, L., Giannaccini, G., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.046 · Cited by 72
Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis
Giatromanolaki, A. N., Sivridis, E., Arelaki, S., & Koukourakis, M. I. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1328714 · Cited by 69
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 69
CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy
Yao, S., He, Z., & Chen, C. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.067 · Cited by 70
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
Kato, Y. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0202-4 · Cited by 72
Compendium of aberrant DNA methylation and histone modifications in cancer
Hattori, N., & Ushijima, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.140 · Cited by 66
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
Leather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 65
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
Teraiya, M., Perreault, H., & Chen, V. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166207 · Cited by 66
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone
Chen, S., Fritchie, K., Wei, S., Ali, N. M., Curless, K. L., Shen, T., Brini, A. T., Latif, F., Sumathi, V. P., Siegal, G. P., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.015 · Cited by 60
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 59
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
Ohba, S., Mukherjee, J., Johannessen, T.-C. A., Mancini, A., Chow, T. T., Wood, M. D., Jones, L. E., Mazor, T., Marshall, R. E., Viswanath, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0696 · Cited by 55
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 53
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis
Cheng, H., Yue, W., Xie, C., Zhang, R., Hu, S., & Wang, Z. (2013) · Tumor Biology · doi:10.1007/s13277-013-0934-5 · Cited by 53
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
Ozair, A., Bhat, V., Alisch, R. S., Khosla, A. A., Kotecha, R. R., Odia, Y., McDermott, M. W., & Ahluwalia, M. S. (2023) · Cancers · doi:10.3390/cancers15041342 · Cited by 51
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
Bledea, R., Vasudevaraja, V., Patel, S. V., Stafford, J. M., Serrano, J., Esposito, G., Tredwin, L. M., Goodman, N. E., Kloetgen, A., Golfinos, J. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53262-7 · Cited by 52
Therapies for IDH-Mutant Gliomas
Nasany, R. A., & de la Fuente, M. I. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01265-3 · Cited by 50
Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3‐mediated mitochondrial and PI3K/Akt–MAPK pathway
Wang, G., Fu, X., Wang, J., Guan, R., Sun, Y., & To, S.-S. T. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26474 · Cited by 51
Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Song, X., Allen, R. A., Dunn, S. T., Fung, K., Farmer, P., Gandhi, S., Ranjan, T., Demopoulos, A. M., Symons, M. H., Schulder, M., et al. (2011) · PubMed Central · Cited by 48
FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression
Charitou, P., Colman, M. J. R., Gerrits, J., van Triest, M. H., Koerkamp, M. J. A. G., Hornsveld, M., Holstege, F. C. P., Verhoeven‐Duif, N. M., & Burgering, B. M. T. (2015) · EMBO Reports · doi:10.15252/embr.201439096 · Cited by 47
Mitochondrial Alterations During Carcinogenesis
Wang, X., Peralta, S., & Moraes, C. T. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00004-6 · Cited by 47
Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
Madala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 46
Rescue of TCA Cycle Dysfunction for Cancer Therapy
Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 47

Authors: Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R.
Affiliations: Agios Pharmaceuticals (United States) (US)
Corresponding author: Fantin, V R
ORCID: Yen, K E
Fantin, V R
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2010-10-25
Volume: 29
Issue: 49
Pages: 6409-6417
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.444
OpenAlex: W2002134084
Cited by: 296
References: 63
Citations by year: 2026: 3 · 2025: 8 · 2024: 11 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 23 · 2016: 16 · 2015: 16 · 2014: 18 · 2013: 29 · 2012: 27
FWCI: 2.93
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: IDH mutation, IDH1, IDH2, glioblastoma, glioma, hematologic malignancies, gain-of-function mutations, alpha-ketoglutarate, prognostic factors, carcinogenesis
MeSH terms: Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Oncogenes, Biomarkers, Tumor, Central Nervous System Neoplasms, Point Mutation, Hematologic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks